Human growth hormone (somatropin) for the treatment of growth failure in children
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta188
Important information about this guidance
Review of NICE technology appraisal guidance 42
This guidance replaces 'NICE technology appraisal guidance 42' issued in May 2002.
The review and re-appraisal of human growth hormone (somatropin) for the treatment of growth failure in children has resulted in a change in the guidance. Human growth hormone (somatropin) is still recommended for the treatment of growth failure in children with growth hormone deficiency, Turner syndrome, Prader–Willi syndrome and chronic renal insufficiency, but there has been an extension of the guidance to include growth failure associated with either of the two following conditions:
-
born small for gestational age with subsequent growth failure at 4 years of age or later
-
short stature homeobox-containing gene (SHOX) deficiency.
A minor correction was made to section 6.1 of the guidance in July 2010. This does not affect the funding direction, which applies from the original date of publication in May 2010
This guidance was developed using the NICE multiple technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp